LBLeif Bäck

Leif Bäck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leif Bäck has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Pedicled Latissimus Dorsi Flap in Head and Neck Reconstruction: An Old Method Revisited

    by Sinikka Suominen, Leif Back, Jyrki Vuola, Patrik Lassus, Tommy Wilkman

    In head and neck cancer patients with significant comorbidities, the reconstructive options are limited, and there is a need for a safe alternative for microvascular flaps without compromising flap size. During the study period, 331 head and neck cancer patients were reconstructed with microvascular tissue flaps. Ten patients requiring large resections were considered to have high risks for long surgery and to be poor candidates for free tissue transfer and thus were reconstructed with a subpectorally tunneled pedicled latissimus dorsi (SP-LD) flap. The flap was raised simultaneously with the tumor resection and tunneled to the head and neck region. The flap was used for reconstruction of oral, mandibular, pharyngeal, or neck defects. Median follow-up was 3.6 years. Median duration of surgery was 7 hours and 17 minutes, and total hospital stay was 20 days. During the follow-up, four patients died of their disease and one from another cause (median of 329 days). We were able to perform large tumor resections with a curative intent and reconstruct major defects in high-risk head and neck cancer patients with a SP-LD flap. It possesses many of the characteristics of a free flap with the benefits of a shorter operation time and less perioperative risk.


  • The developing management of esthesioneuroblastoma: a single institution experience

    by Leif Bäck, Minna Oinas, Petra Pietarinen-Runtti, Kauko Saarilahti, Jyrki Vuola, Riste Saat, Juha Öhman, Caj Haglund, Mika Niemelä, Ilmo Leivo, et al.


  • The impact of pretreatment assessment of oropharynx on interstitial soft palate radiofrequency surgery outcome—a multi-center study in patients with habitual snoring

    by Leif J. J. Bäck, Petri Koivunen, Ilmari Pyykkö, Brit K. Stene, Antti A. Mäkitie

    Interstitial radiofrequency (RF) surgery of the soft palate (SP) is an established option in the treatment of habitual snoring. The decision-making process in the management of habitual snoring would benefit from diagnostic guidelines for oropharyngeal findings. Our aim was to investigate the correlation of systematic clinical pretreatment oropharyngeal examination scores with the efficacy of interstitial RF surgery of SP in a multi-center study. Seventy-four patients (58 (78%) males and 16 (22%) females) with the median age of 42 years (range, 23–64), pre-treatment BMI of 25.6 kg/m2 (range, 20.0–28.0), and preoperative AHI of three events/h (range, 0–10), received a single session of RF surgery. Thirty-two, five, 16, and 21 patients, respectively, were treated at the participating centers with a follow-up time of 13 weeks (range 12–16). The primary outcome measure was the efficacy of the treatment on snoring assessed by the patient and the bed partner with visual analog scale (VAS). The snoring showed a significant change demonstrating decreased snoring (VASpatpre 7 (range, 5–10) ≥VASpatpost 4.25 (range, 1–8), P < 0.001, VASbedppre 8 (range, 4–10) ≥VASbedppost 5 (range, 1–10), P < 0.001). Twenty-one patients (28.4%) experienced a successful treatment outcome. The increased grade of the uvula had a negative impact on the snoring results. Systematic clinical pretreatment oropharyngeal examination scores showed that the increasing grade of the uvula correlated significantly with the short-term post-treatment change in snoring. We suggest that patients with habitual snoring and uvula grade III should be initially treated with SP interstitial RF surgery and concomitant uvular surgery. A grading tool is proposed for oropharyngeal examination to help in the most appropriate treatment decision for each individual snoring patient.


    • 1 January 2011
      • Vol. 127  (18) , 1971-7

    [Current issues in the treatment of pharyngeal cancer].

    by Jussi Laranne, Kauko Saarilahti, Ilmo Leivo, Leif Bäck, Reidar Grénman, Petri Koivunen, Matti Pukkila, Antti Mäkitie

    In Finland over the past few years approximately 100 new cases of oro- and hypopharyngeal cancer have been diagnosed annually. Most of these are squamous cell carcinomas. The incidence of these diseases increases after age 45. Minor and nonspecific local symptoms caused by the primary tumor are common to pharyngeal cancers at the initial stage of the disease. Often the diagnosis is delayed and the search for the primary tumor is begun only after detection of neck metastases. They occur in 60 to 80% at the time of diagnosis. Among the risk factors, smoking and heavy drinking are most important.

    • 1 January 2011
      • Vol. 127  (18) , 1986-91

    [Therapeutic results in oral cancer--what has been learned?].

    by Antti Mäkitie, Harri Keski-Säntti, Kauko Saarilahti, Leif Bäck, Risto Kontio, Reidar Grénman, Petri Koivunen, Jussi Laranne

    Oral cancer is the most common head and neck cancer in Finland. The number of new cases has been on a steady rise over the last decades. Smoking and heavy drinking are the most important risk factors. The role of papilloma virus infection is under active research, albeit with a smaller role than in oropharyngeal cancer, for instance. Surgical excision of the tumor is usually the first-line treatment. Pathoanatomical investigation of the primary tumor and cervical lymph nodes is essential in evaluating the need of adjuvant therapy. The prognosis of oral cancer has improved as a result of early detection and development of treatment modalities.

    • 1 June 2010
      • Vol. 39  (3) , 269-76

    Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer.

    by Kauko Saarilahti, Petri Bono, Mikael Kajanti, Leif Bäck, Ilmo Leivo, Timo Joensuu, Jorma Isola, Antti A Mäkitie

    To examine a series of head and neck squamous cell cancer (HNSCC) patients treated with combined gefitinib and chemoradiotherapy (CRT) regarding treatment efficacy and tolerability and correlation with epidermal growth factor receptor (EGFR) factors. Fifteen patients with locally advanced HNSCC were included in the study. The patients were scheduled to take gefitinib 250 mg in combination with concurrent radiotherapy (RT) +/- concomitant cisplatin. EGFR expression, activation and amplification; serum vascular endothelial growth factor (S-VEGF); and microvessel density were determined. Locoregional tumour control at 3 months was achieved in 79% of the patients. The treatment was reasonably well tolerated. A tendency toward a correlation between complete tumour response and EGFR amplification was observed (p = .057). Patients with activated EGFR did not have significantly more complete responses than patients with no EGFR activation (p = .10). The baseline S-VEGF levels seemed to be higher in patients with HNSCC than in 40 healthy controls (p = .076). The combination of gefitinib and RT with concurrent cisplatin was feasible. EGFR amplification status may correlate with the treatment response in HNSCC patients treated by gefitinib and CRT. S-VEGF level does not seem to correlate with treatment outcome.


  • Management of facial nerve schwannoma: A single institution experience

    by Leif Bäck, Tero Heikkilä, Fabricio Passador-Santos, Riste Saat, Ilmo Leivo, Antti A. Mäkitie

    Conclusion: Difficulties in diagnosis, conservative initial steps in the management algorithm and intraoperative risks for facial nerve (FN) injury are divisive features for this tumour entity. Objective: The aim of the present study was to investigate the management and outcome of FN schwannomas (FNSs) at a tertiary referral centre and academic institution in a 30-year material. Methods: Data on age, sex, symptoms, tumour location, histopathological characteristics, imaging, management and outcome were retrospectively recorded. Results: Ten cases (six males, 60%), with a median age of 34.5 years (range 19–75 years) were identified. Five of the patients had intact FN function at the time of diagnosis. Five of the tumours were intraparotid and five were located in the temporal bone. Preoperative fine needle aspirations were non-diagnostic in all of the four patients presenting with a parotid mass. Nine patients were managed surgically. One patient is currently under conservative follow-up for a parotid schwannoma (diagnosed with magnetic resonance imaging) with intact FN function. No malignant schwannomas were encountered. The clinical outcome and histology will be discussed.


    • 1 October 2009
      • Vol. 38  (5) , 537-44

    Assessment of submucosal radiofrequency tonsil reduction by magnetic resonance imaging.

    by Leif Bäck, Pekka Tervahartiala, Anneli Piilonen, Antti Mäkitie, Jukka Ylikoski

    The primary objective was to assess the efficacy of submucosal radiofrequency tonsil reduction (SRFTR) in adults by magnetic resonance imaging (MRI). The secondary objective was to evaluate the morbidity of SRFTR. A prospective, longitudinal clinical study with a follow-up time of 12 months was conducted of 10 consecutive patients with the median age of 24.5 years (range 19-55 years) with obstructive palatine tonsil hypertrophy. SRFTR was delivered in an outpatient setting in a tertiary care centre, academic teaching hospital. The change in tonsillar volume after SRFTR was evaluated with MRI by two radiologists independently and blinded to the treatment results. The morbidity was assessed with a visual analogue scale (VAS), a questionnaire for the pain medication needed, and inflammatory laboratory parameters. VAS and use of pain medication results were compared with those of two earlier cohort groups undergoing conventional tonsillectomy with two different techniques at our department. The tonsil volume reduced significantly with a median reduction in the total tonsil volume of 12.6% (range 3.7-41.5%, pretreatment vs posttreatment volume, p < .01). VAS of the morbidity symptoms and the amount of pain medication needed were significantly lower in the SRFTR group than in the two historical tonsillectomy groups. The laboratory parameters showed a significant change. SRFTR in adults with obstructive palatine tonsil hypertrophy is a minimally invasive procedure causing a tonsil volume reduction demonstrated by MRI. The procedure seems to be associated with acceptable morbidity.


  • Radiofrequency surgery of the soft palate in the treatment of mild obstructive sleep apnea is not effective as a single‐stage procedure: A randomized single‐blinded placebo‐controlled trial

    by Leif J. J. Bäck, Tommi Liukko, Irma Rantanen, Jaakko S. Peltola, Markku Partinen, Jukka Ylikoski, Antti A. Mäkitie

    Objectives/Hypothesis: Radiofrequency (RF) surgery of the soft palate (SP) is an established treatment option for the treatment of snoring. Due to its minimally invasive character, it has received attention in the management of mild obstructive sleep apnea syndrome (OSAS).Study Design: The aim of this study was to assess the efficacy and the occurrence of adverse events after single‐stage SP RF surgery in patients with mild OSAS in a randomized single‐blinded placebo‐controlled trial in an outpatient department at a tertiary care center, academic teaching hospital.Methods: Thirty‐two patients with mild OSAS (apnea‐hypopnea index [AHI] 5–15, body mass index P = .628), nor were trends of a diminishing effect on symptoms of mild OSAS found in the treatment arms. No significant changes in the soft tissue airway parameters occurred. One patient (5.9%) in the active treatment group was cured.Conclusions: RF surgery of SP is not recommended as a single‐stage approach in mild OSAS. Laryngoscope, 2009


  • Radiofrequency ablation treatment of soft palate for patients with snoring: A systematic review of effectiveness and adverse effects

    by Leif J. J. Bäck, Maija L. Hytönen, Risto P. Roine, Antti O. V. Malmivaara

    Objective: To assess the effectiveness and adverse effects of radiofrequency ablation (RFA) of soft palate (SP) in snoring. Study Design: Systematic search of electronic databases. Only articles published in peer‐reviewed journals were evaluated. Included were controlled or prospective studies with at least 10 adults (≥18 years of age) without moderate/severe obstructive sleep apnea. Results: Of the 159 articles identified, 30 met the inclusion criteria: two randomized controlled trials (RCT), four clinical controlled trials, and 24 prospective uncontrolled studies. The only placebo controlled RCT indicated SP RFA to be superior compared to placebo. The other RCT, comparing different radiofrequency ablation generators, showed no evidence of differences in snoring treatment efficacy, and only minor differences in patient discomfort. In two of the controlled trials snoring relief obtained by SP RFA was comparable, and in three of them associated with less postoperative pain than other interventions. Radiologic results were contradictory with some trials reporting significant changes of the upper airways, whereas others did not. Neither long‐term side effects nor major adverse events have been reported after. Conclusions: The review provides evidence that SP RFA is an intervention causing less postoperative pain than others, and the risk of adverse effects for the patient seems to be small. It may reduce symptoms of snoring, at least in the short term. However, most of the published SP RFA literature is based on observational studies with a short follow‐up time, which precludes solid conclusions about the effectiveness of the procedure. Laryngoscope, 2009